Collaboration Agreement

No definition available.

Name:	regn_CollaborationAgreementAbstract
Namespace Prefix:	regn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner.

+ References

No definition available.

+ Details

Name:	regn_Contingentreimbursementobligation
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Our share of profits/losses related to commercialization of products by our collaborator based on sales outside the United States. Under the terms of our collaboration agreement, we share profits/losses with our collaborator on commercialization of products.

+ References

No definition available.

+ Details

Name:	regn_Netprofitlossfromcommercializationofproductsundercollaborationagreement
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue realized from sharing of profits/losses on commercialized products, reimbursement of research and development expenses, and other transactions with our collaborator Bayer during the period.

+ References

No definition available.

+ Details

Name:	regn_OtherCollaborationRevenue
Namespace Prefix:	regn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration.

+ References

No definition available.

+ Details

Name:	regn_PercentageofdevelopmentcostfortheterritoryoutsidetheUnitedStatespreviouslyrequiredtobepaidforunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of global development cost to be paid by the collaboration partner under the collaboration

+ References

No definition available.

+ Details

Name:	regn_Percentageofglobaldevelopmentcosttobepaidbythecollaborationpartnerunderthecollaboration
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments.

+ References

No definition available.

+ Details

Name:	regn_RevenuebasedonpercentageofannualsalesinJapan
Namespace Prefix:	regn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date, net of allowance for doubtful accounts, of account and note receivables due from other than related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccountsAndNotesReceivableNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q1(c))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b).Q2)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(b))
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3(c).Q3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_CollaborationAgreementWithBayerHealthcareLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_EYLEAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_Ang2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_Ang2AntibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=regn_Ang2antibodyandPDGFRbetaantibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreements (Bayer HealthCare LLC) (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
	Mar. 31, 2016	Aug. 31, 2007	Oct. 31, 2006	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Collaboration Agreements [Line Items]
Accounts receivable from Bayer				$ 242,014	$ 175,263
Deferred revenue, current portion				320,138	231,664
Other Collaboration Revenue				938,052	744,270	$ 580,488
Collaboration Agreement with Bayer HealthCare LLC
Collaboration Agreement [Abstract]
Contingent reimbursement obligation				251,000
Collaboration Agreements [Line Items]
Deferred Revenue, Additions		$ 20,000	$ 75,000
Net profit (loss) from commercialization of products under collaboration agreement				802,298	649,232	466,667
Revenue Recognition, Milestone Method, Revenue Recognized				0	0	15,000
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned				13,325	9,010	8,887
Other Collaboration Revenue				874,257	710,769	560,020
Contracts Revenue				58,634	52,527	69,466
EYLEA
Collaboration Agreements [Line Items]
Deferred revenue, current portion				68,734	62,373
Ang2
Collaboration Agreements [Line Items]
Deferred revenue, current portion				0	45,739
Ang2 Antibody [Member]
Collaboration Agreements [Line Items]
Deferred Revenue, Additions	$ 50,000
Percentage of global development cost to be paid by the collaboration partner under the collaboration	25.00%
Percentage of development cost for the territory outside the United States to be paid for under the collaboration	50.00%
Ang2 antibody and PDGFR-beta antibody
Collaboration Agreements [Line Items]
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned				17,841	18,327	10,075
Other Collaboration Revenue				63,795	33,501	20,468
Contracts Revenue				$ 45,954	$ 15,174	$ 10,393
Minimum \| Collaboration Agreement with Bayer HealthCare LLC
Collaboration Agreements [Line Items]
Revenue based on percentage of annual sales in Japan				33.50%
Maximum \| Collaboration Agreement with Bayer HealthCare LLC
Collaboration Agreements [Line Items]
Revenue based on percentage of annual sales in Japan				40.00%